Reward-based Technology for Opioid Use Disorder
(OARSCM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common and associated with poor outcomes. This project will utilize a digital mobile platform, Opioid Addiction Recovery Support with contingency management (OARSCM), to increase MAT treatment initiation and adherence among OUD patients recruited from emergency departments and inpatient acute care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on starting and adhering to Suboxone treatment for opioid use disorder.
Is the reward-based technology for opioid use disorder safe for humans?
How is the MyMAT and OARSCM Software Application treatment different from other treatments for opioid use disorder?
The MyMAT and OARSCM Software Application treatment is unique because it uses a digital platform to provide reward-based support and motivational coaching, which can help improve adherence to medication-assisted treatment (MAT) and reduce opioid misuse. This approach is different from traditional treatments as it integrates technology to offer real-time interventions and support, making it more accessible and potentially more engaging for patients.14567
What data supports the effectiveness of the treatment MyMAT Software Application for opioid use disorder?
Research shows that digital tools like mobile apps can help people understand and stick to medication-assisted treatment (MAT) for opioid use disorder. A study on a similar app, 'uMAT-R', found it could improve knowledge about recovery and the benefits of MAT, which are common barriers to starting treatment.45789
Who Is on the Research Team?
Rachel Davis-Martin, PhD
Principal Investigator
University of Massachusetts Chan Medical School
Are You a Good Fit for This Trial?
Adults over 18 with opioid use disorder seeking acute care at UMass hospitals, diagnosed with OUD and suitable for outpatient Suboxone treatment. Excluded if they lack a compatible smartphone or access to the app, are not in central MA region, have legal issues that may lead to imprisonment, can't understand study requirements, don't speak English, already in the trial or unwilling to participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Suboxone treatment with contingency management interventions for 12 weeks
Follow-up
Participants are monitored for treatment adherence and opioid use through clinical records and telephone assessments
Open-label extension (optional)
Participants may continue to receive treatment and monitoring beyond the initial study period
What Are the Treatments Tested in This Trial?
Interventions
- MyMAT Software Application
- OARSCM Software Application
MyMAT Software Application is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Q2i, LLC
Lead Sponsor
University of Massachusetts, Worcester
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
University of Massachusetts Chan Medical School
Collaborator